Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Details Its HCV Dominance As AbbVie Seeks Meaningful Market Position

Executive Summary

Gilead holds a 90% market share in the U.S. hepatitis C market, with Harvoni capturing roughly 85% of the aggregate treatment population. AbbVie hopes an imminent Japanese approval and a second-generation regimen will boost its HCV business.



Related Companies